carvedilol has been researched along with Myocarditis in 24 studies
Myocarditis: Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol in 3 doses (2, 10, and 30 mg/kg) was given daily to 3 study groups of rats (n = 8) with experimental autoimmune myocarditis by gastric gavage for 3 weeks." | 7.88 | Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application. ( Biczysko, W; Ceremuga, I; Dziegiel, P; Haczkiewicz, K; Kobierzycki, C; Kwiatkowska, J; Piasecki, T; Podhorska-Okolow, M; Sapa, A; Skrzypiec-Spring, M; Szelag, A; Wozniak, M, 2018) |
| "This study aims to compare the effects of carvedilol and metoprolol in alleviating viral myocarditis (VMC) induced by coxsackievirus B3 (CVB3) in mice." | 7.80 | Carvedilol has stronger anti-inflammation and anti-virus effects than metoprolol in murine model with coxsackievirus B3-induced viral myocarditis. ( Chen, C; Chen, Q; Chen, Y; Chu, M; Jiang, J; Pan, L; Qian, Y; Wang, D; Zhou, A, 2014) |
| "This study was therefore designed to examine the effects of carvedilol on the transcriptional factor CREB in a murine model of acute viral myocarditis." | 7.79 | Effects of carvedilol treatment on cardiac cAMP response element binding protein expression and phosphorylation in acute coxsackievirus B3-induced myocarditis. ( Li-Sha, G; Na-Dan, Z; Teng, Z; Yi-He, C; Yue-Chun, L, 2013) |
| "The study was designed to compare the effects of ivabradine and carvedilol in acute viral myocarditis." | 7.78 | Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis. ( Jia-Feng, L; Li-Sha, G; Na-Dan, Z; Qin, L; Teng, Z; Xue-Qiang, G; Yue-Chun, L, 2012) |
| "To observe the effects of carvedilol on the expression of Bcl-2, Bax and Fas in autoimmune myocarditis (AM)." | 7.77 | [Effects of carvedilol on cardiomyocyte apoptosis in autoimmune myocarditis in mice]. ( Chen, Q; Jiang, JB; Qiu, HX; Rong, X; Wang, ZQ; Wu, HP; Wu, RZ; Xiang, RL, 2011) |
| "The cardioprotective effects of carvedilol were studied in a rat model of experimental autoimmune myocarditis (EAM)." | 7.76 | Immunoregulatory effects of carvedilol on rat experimental autoimmune myocarditis. ( Chen, L; Gu, W; Kong, Y; Li, W; Liu, H; Yang, N, 2010) |
| "Carvedilol, a nonselective beta-blocker with additional alpha1-adrenergic blocking and antioxidant properties, has been shown to be cardioprotective in experimental myocarditis." | 7.74 | Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. ( Ji-Fei, T; Jia-Feng, L; Jiang-Hua, R; Li-Sha, G; Peng, C; Peng-Lin, Y; Yue-Chun, L; Zhan-Qiu, Y, 2008) |
| "In a coxsackievirus B3 murine myocarditis model (BALB/c), effects of carvedilol and metoprolol on myocardial cytokine expression, inflammatory cell infiltration and MMP/TIMP profiles were investigated." | 7.73 | Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response. ( Chandrasekharan, K; Li, J; Noutsias, M; Pauschinger, M; Peter Schwimmbeck, L; Poller, W; Rutschow, S; Schultheiss, HP; Tschope, C; Weitz, A; Westermann, D; Zeichhardt, H, 2005) |
| "This study was designed to examine the effects of carvedilol in a murine model of viral myocarditis induced by encephalomyocarditis virus (EMCV) infection." | 7.72 | Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. ( Matsumori, A; Nishio, R; Sasayama, S; Shioi, T, 2003) |
| "We investigated whether carvedilol protects against experimental autoimmune myocarditis (EAM) attributing to antioxidant properties." | 7.72 | Cardioprotective effects of carvedilol on acute autoimmune myocarditis. ( Kishimoto, C; Nimata, M; Shioji, K; Yuan, Z, 2004) |
| "Carvedilol, a vasodilating nonselective beta-adrenoceptor antagonist, but not metoprolol, a selective beta1-adrenoceptor antagonist, has been shown to increase the production of cardiac antiinflammatory cytokines in experimental myocarditis." | 7.72 | Hemodynamic characterization of left ventricular function in experimental coxsackieviral myocarditis: effects of carvedilol and metoprolol. ( Noutsias, M; Pauschinger, M; Rutschow, S; Schultheiss, HP; Schwimmbeck, PL; Steendijk, P; Tschöpe, C; Weitz, A; Westermann, D, 2004) |
| "Carvedilol is a nonselective β-blocker with α1-adrenergic blocking and antioxidant properties." | 6.48 | The mechanism of carvedilol in experimental viral myocarditis. ( Jia-Feng, L; Li-Sha, G; Xue-Qiang, G; Yue-Chun, L, 2012) |
| "Carvedilol in 3 doses (2, 10, and 30 mg/kg) was given daily to 3 study groups of rats (n = 8) with experimental autoimmune myocarditis by gastric gavage for 3 weeks." | 3.88 | Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application. ( Biczysko, W; Ceremuga, I; Dziegiel, P; Haczkiewicz, K; Kobierzycki, C; Kwiatkowska, J; Piasecki, T; Podhorska-Okolow, M; Sapa, A; Skrzypiec-Spring, M; Szelag, A; Wozniak, M, 2018) |
| "This study was therefore designed to examine the effects of carvedilol on the transcriptional factor CREB in a murine model of acute viral myocarditis." | 3.79 | Effects of carvedilol treatment on cardiac cAMP response element binding protein expression and phosphorylation in acute coxsackievirus B3-induced myocarditis. ( Li-Sha, G; Na-Dan, Z; Teng, Z; Yi-He, C; Yue-Chun, L, 2013) |
| "The study was designed to compare the effects of ivabradine and carvedilol in acute viral myocarditis." | 3.78 | Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis. ( Jia-Feng, L; Li-Sha, G; Na-Dan, Z; Qin, L; Teng, Z; Xue-Qiang, G; Yue-Chun, L, 2012) |
| "To observe the effects of carvedilol on the expression of Bcl-2, Bax and Fas in autoimmune myocarditis (AM)." | 3.77 | [Effects of carvedilol on cardiomyocyte apoptosis in autoimmune myocarditis in mice]. ( Chen, Q; Jiang, JB; Qiu, HX; Rong, X; Wang, ZQ; Wu, HP; Wu, RZ; Xiang, RL, 2011) |
| "The cardioprotective effects of carvedilol were studied in a rat model of experimental autoimmune myocarditis (EAM)." | 3.76 | Immunoregulatory effects of carvedilol on rat experimental autoimmune myocarditis. ( Chen, L; Gu, W; Kong, Y; Li, W; Liu, H; Yang, N, 2010) |
| "Carvedilol, a nonselective beta-blocker with additional alpha1-adrenergic blocking and antioxidant properties, has been shown to be cardioprotective in experimental myocarditis." | 3.74 | Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. ( Ji-Fei, T; Jia-Feng, L; Jiang-Hua, R; Li-Sha, G; Peng, C; Peng-Lin, Y; Yue-Chun, L; Zhan-Qiu, Y, 2008) |
| "In a coxsackievirus B3 murine myocarditis model (BALB/c), effects of carvedilol and metoprolol on myocardial cytokine expression, inflammatory cell infiltration and MMP/TIMP profiles were investigated." | 3.73 | Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response. ( Chandrasekharan, K; Li, J; Noutsias, M; Pauschinger, M; Peter Schwimmbeck, L; Poller, W; Rutschow, S; Schultheiss, HP; Tschope, C; Weitz, A; Westermann, D; Zeichhardt, H, 2005) |
| "This study was designed to examine the effects of carvedilol in a murine model of viral myocarditis induced by encephalomyocarditis virus (EMCV) infection." | 3.72 | Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. ( Matsumori, A; Nishio, R; Sasayama, S; Shioi, T, 2003) |
| "We investigated whether carvedilol protects against experimental autoimmune myocarditis (EAM) attributing to antioxidant properties." | 3.72 | Cardioprotective effects of carvedilol on acute autoimmune myocarditis. ( Kishimoto, C; Nimata, M; Shioji, K; Yuan, Z, 2004) |
| "Carvedilol, a vasodilating nonselective beta-adrenoceptor antagonist, but not metoprolol, a selective beta1-adrenoceptor antagonist, has been shown to increase the production of cardiac antiinflammatory cytokines in experimental myocarditis." | 3.72 | Hemodynamic characterization of left ventricular function in experimental coxsackieviral myocarditis: effects of carvedilol and metoprolol. ( Noutsias, M; Pauschinger, M; Rutschow, S; Schultheiss, HP; Schwimmbeck, PL; Steendijk, P; Tschöpe, C; Weitz, A; Westermann, D, 2004) |
| " The cardioprotective properties of carvedilol, a vasodilating beta-adrenoceptor-blocking agent, were studied in a rat model of dilated cardiomyopathy after autoimmune myocarditis." | 3.71 | Effects of carvedilol on cardiac function and cardiac adrenergic neuronal damage in rats with dilated cardiomyopathy. ( Aizawa, Y; Ashino, H; Fuse, K; Kodama, M; Nakazawa, M; Takahashi, T; Tanabe, N; Tazawa, S; Wahed, MI; Watanabe, K, 2002) |
| "The cardioprotective properties of carvedilol (a vasodilating beta-adrenoceptor blocking agent) were studied in a rat model of dilated cardiomyopathy induced by autoimmune myocarditis." | 3.70 | Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. ( Aizawa, Y; Fuse, K; Hanawa, H; Hasegawa, G; Higuchi, H; Hirono, S; Ito, M; Kato, K; Kodama, M; Naito, M; Nakazawa, M; Ohta, Y; Tanabe, N; Watanabe, K, 2000) |
| "Carvedilol is a nonselective β-blocker with α1-adrenergic blocking and antioxidant properties." | 2.48 | The mechanism of carvedilol in experimental viral myocarditis. ( Jia-Feng, L; Li-Sha, G; Xue-Qiang, G; Yue-Chun, L, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 14 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Zijll Langhout, M | 1 |
| Wolters, M | 1 |
| Horvath, KM | 1 |
| Thiesbrummel, H | 1 |
| Smits, P | 1 |
| van Bolhuis, H | 1 |
| van der Hulst, V | 1 |
| Riezebos, R | 1 |
| Skrzypiec-Spring, M | 1 |
| Haczkiewicz, K | 1 |
| Sapa, A | 1 |
| Piasecki, T | 1 |
| Kwiatkowska, J | 1 |
| Ceremuga, I | 1 |
| Wozniak, M | 1 |
| Biczysko, W | 1 |
| Kobierzycki, C | 1 |
| Dziegiel, P | 1 |
| Podhorska-Okolow, M | 1 |
| Szelag, A | 1 |
| Guang-Yi, C | 1 |
| Li-Sha, G | 5 |
| Yue-Chun, L | 5 |
| Yi-He, C | 1 |
| Na-Dan, Z | 2 |
| Teng, Z | 2 |
| Wang, D | 1 |
| Chen, Y | 1 |
| Jiang, J | 1 |
| Zhou, A | 1 |
| Pan, L | 1 |
| Chen, Q | 2 |
| Qian, Y | 1 |
| Chu, M | 1 |
| Chen, C | 1 |
| Teoh, JP | 1 |
| Park, KM | 1 |
| Broskova, Z | 1 |
| Jimenez, FR | 1 |
| Bayoumi, AS | 1 |
| Archer, K | 1 |
| Su, H | 1 |
| Johnson, J | 1 |
| Weintraub, NL | 1 |
| Tang, Y | 1 |
| Kim, IM | 1 |
| Liu, H | 1 |
| Li, W | 1 |
| Gu, W | 1 |
| Kong, Y | 1 |
| Yang, N | 1 |
| Chen, L | 1 |
| Pergola, G | 1 |
| Cascone, A | 1 |
| Russo, M | 1 |
| Li, YC | 2 |
| Ge, LS | 2 |
| Yang, PL | 1 |
| Tang, JF | 1 |
| Lin, JF | 2 |
| Chen, P | 1 |
| Guan, XQ | 2 |
| Dabrowski, R | 1 |
| Pedzich-Placha, E | 1 |
| Wu, RZ | 1 |
| Wu, HP | 1 |
| Wang, ZQ | 1 |
| Rong, X | 1 |
| Jiang, JB | 1 |
| Qiu, HX | 1 |
| Xiang, RL | 1 |
| Xue-Qiang, G | 2 |
| Jia-Feng, L | 3 |
| Qin, L | 1 |
| Luo, Q | 1 |
| Chen, YH | 1 |
| Zhou, ND | 1 |
| Zhang, T | 1 |
| Nishio, R | 1 |
| Shioi, T | 1 |
| Sasayama, S | 1 |
| Matsumori, A | 1 |
| Yuan, Z | 2 |
| Shioji, K | 2 |
| Kihara, Y | 1 |
| Takenaka, H | 1 |
| Onozawa, Y | 1 |
| Kishimoto, C | 2 |
| Nimata, M | 1 |
| Tschöpe, C | 2 |
| Westermann, D | 2 |
| Steendijk, P | 1 |
| Noutsias, M | 2 |
| Rutschow, S | 2 |
| Weitz, A | 2 |
| Schwimmbeck, PL | 1 |
| Schultheiss, HP | 2 |
| Pauschinger, M | 2 |
| Chandrasekharan, K | 1 |
| Peter Schwimmbeck, L | 1 |
| Zeichhardt, H | 1 |
| Poller, W | 1 |
| Li, J | 1 |
| Jiang-Hua, R | 1 |
| Peng-Lin, Y | 1 |
| Ji-Fei, T | 1 |
| Peng, C | 1 |
| Zhan-Qiu, Y | 1 |
| Fett, JD | 1 |
| Watanabe, K | 2 |
| Ohta, Y | 1 |
| Nakazawa, M | 2 |
| Higuchi, H | 1 |
| Hasegawa, G | 1 |
| Naito, M | 1 |
| Fuse, K | 2 |
| Ito, M | 1 |
| Hirono, S | 1 |
| Tanabe, N | 2 |
| Hanawa, H | 1 |
| Kato, K | 1 |
| Kodama, M | 2 |
| Aizawa, Y | 2 |
| Takahashi, T | 1 |
| Wahed, MI | 1 |
| Ashino, H | 1 |
| Tazawa, S | 1 |
| Merlet, P | 1 |
| Hittinger, L | 1 |
| Dubois-Randé, JL | 1 |
| Castaigne, A | 1 |
2 reviews available for carvedilol and Myocarditis
| Article | Year |
|---|---|
Role of Heart Rate Reduction in the Management of Myocarditis.
Topics: Adrenergic beta-Antagonists; Animals; Cardiovascular Agents; Carvedilol; Heart Rate; Humans; Inflamm | 2018 |
The mechanism of carvedilol in experimental viral myocarditis.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Mice; Myocardi | 2012 |
22 other studies available for carvedilol and Myocarditis
| Article | Year |
|---|---|
Clinical signs, diagnostics and successful treatment of a myocarditis in an adult chimpanzee (Pan troglodytes).
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Ape Diseases; Carbazoles; Carvedilol; | 2017 |
Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Autoimmune Diseases; Carbazoles; Carvedilol; Di | 2018 |
Effects of carvedilol treatment on cardiac cAMP response element binding protein expression and phosphorylation in acute coxsackievirus B3-induced myocarditis.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coxsackievirus Infectio | 2013 |
Carvedilol has stronger anti-inflammation and anti-virus effects than metoprolol in murine model with coxsackievirus B3-induced viral myocarditis.
Topics: Animals; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; Cytokines; Enterovirus B, Human; Metoprolol | 2014 |
Identification of gene signatures regulated by carvedilol in mouse heart.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiomyopathies; Carvedilol; Gene Expression Regu | 2015 |
Immunoregulatory effects of carvedilol on rat experimental autoimmune myocarditis.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Atrial Natriuretic Factor; Autoi | 2010 |
Acute pericarditis and myocarditis by Toxoplasma gondii in an immunocompetent young man: a case report.
Topics: Acute Disease; Adult; Aluminum Hydroxide; Antibodies, Protozoan; Carbazoles; Carvedilol; Chest Pain; | 2010 |
Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction.
Topics: Adrenergic Antagonists; Aldehydes; Animals; Body Weight; Carbazoles; Carvedilol; Electrocardiography | 2010 |
[Improvement of left ventricular function during combined carvedilol, ramipril and spironolactone therapy after myocarditis in patient treated earlier by chemotherapy due to Hodgkin's lymphoma - 3-years follow-up].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol | 2010 |
[Effects of carvedilol on cardiomyocyte apoptosis in autoimmune myocarditis in mice].
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Autoimmune Diseases; bcl-2-Associated X Protein; Ca | 2011 |
Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis.
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Benzazepines; Carbazoles; Carvedilol; Coxsackieviru | 2012 |
Ivabradine inhibits the production of proinflammatory cytokines and inducible nitric oxide synthase in acute coxsackievirus B3-induced myocarditis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Benzazepines; Carbazoles; Carvedilol; Coxsackievir | 2013 |
Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiovirus Infections; Carvedilol; Dose-Response | 2003 |
Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Antioxidants; Autoimm | 2004 |
Cardioprotective effects of carvedilol on acute autoimmune myocarditis.
Topics: Administration, Oral; Animals; Autoimmune Diseases; Carbazoles; Cardiotonic Agents; Carvedilol; Dose | 2004 |
Hemodynamic characterization of left ventricular function in experimental coxsackieviral myocarditis: effects of carvedilol and metoprolol.
Topics: Animals; Carbazoles; Carvedilol; Coxsackievirus Infections; Male; Metoprolol; Mice; Mice, Inbred BAL | 2004 |
Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coxsackievirus Infections; Interleukin | 2005 |
Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Antioxidants; Carbazo | 2008 |
Case 36-2007: a woman with rash, fever, and hypotension.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Female; Humans; Hypotensi | 2008 |
Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy.
Topics: Animals; Body Weight; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Disease Progression; Endomyoc | 2000 |
Effects of carvedilol on cardiac function and cardiac adrenergic neuronal damage in rats with dilated cardiomyopathy.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Adrenergic Fibers; Animals; Autoimmune Diseases; | 2002 |
Myocardial adrenergic dysinnervation in dilated cardiomyopathy: cornerstone or epiphenomenon?
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Adrenergic Fibers; Animals; Carbazoles; Cardiomy | 2002 |